Sensex, Nifty Flat In Opening; Reliance, Cadila Up 2%; ITC Drags

Cadila Healthcare gained more than 2 percent after subsidiary Zydus Cadila received regulatory approvals to launch tetravalent inactivated influenza vaccine for seasonal flu in India.
The company has received approvals from Drug Controller General of India, Central Drugs Standard Control Organisation and Central Drug Laboratory to market the tetravalent inactivated influenza vaccine Vaxiflu 4 for seasonal flu, Cadila Healthcare said in a filing to BSE. 

For more information Call us ✆ +91 7400-734000 or Visit Dollar Advisory